The cross-priming pathway: A portrait of an intricate immune system

Scandinavian Journal of Immunology

Volumn 65, Issue 4, 2007, Pages 311-319

  Basta, S ^a   Alatery, A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROSS PRESENTATION; DENDRITIC CELL; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MODELS, IMMUNOLOGICAL;

EID: 33947601157     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.01909.x     Document Type: Review

References (100)

1. Makela PH. Vaccines, coming of age after 200 years. FEMS Microbiol Rev 2000;24:9-20.
2. Bhardwaj N. Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Mol Med 2001;7:388-94.
3. Arina A, Tirapu I, Alfaro C et al. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming. Exp Hematol 2002;30:1355-64.
4. + T cells in vivo: the key to rational vaccine design. Annu Rev Immunol 2005;23:651-82.
5. Shen L, Rock KL. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr Opin Immunol 2006;18:85-91.
6. Heath WR, Carbone FR. Cytotoxic T lymphocyte activation by cross-priming. Curr Opin Immunol 1999;11:314-8.
7. + T cells: cross-priming in infectious diseases. Curr Opin Immunol 2001;13:437-41.
8. Melief CJ. Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur J Immunol 2003;33:2645-54.
9. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255-8.
10. Gale M Jr, Tan SL, Katze MG. Translational control of viral gene expression in eukaryotes. Microbiol Mol Biol Rev 2000;64:239-80.
11. Yewdell JW, Anton LC, Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules. J Immunol 1996;157:1823-6.
12. Yewdell JW. Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol 2001;11:294-7.
13. Golovina TN, Morrison SE, Eisenlohr LC. The impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing. J Immunol 2005;174:2763-9.
14. Rock KL, York IA, Saric T, Goldberg AL. Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 2002;80:1-70.
15. Rock KL, York IA, Goldberg AL. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 2004;5:670-7.
16. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976;143:1283-8.
17. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988;54:777-85.
18. Yewdell JW, Bennink JR, Hosaka Y. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science 1988;239:637-40.
19. Basta S, Stoessel R, Basler M, van den Broek M, Groettrup M. Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J Immunol 2005;175:796-805.
20. + T cell responses to influenza A virus: roles for cross-presentation and lysis-independent immunodomination. J Immunol 2004;173:5021-7.
21. + T cell cross-priming via transfer of proteasome substrates. Science 2004;304:1318-21.
22. + T cells by viral and tumor antigens is a robust phenomenon. Eur J Immunol 2004;34:194-9.
23. Cho Y, Basta S, Chen WS, Bennink JR, Yewdell JW. Heat-aggregated noninfectious influenza virus induces a more balanced CD8(+)-T-lymphocyte immunodominance hierarchy than infectious virus. J Virol 2003;77:4679-84.
24. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999;398:77-80.
25. Sigal LJ, Rock KL. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation. J Exp Med 2000;192:1143-50.
26. Ramirez MC, Sigal LJ. Macrophages and dendritic cells use the cytosolic pathway to rapidly cross-present antigen from live, vaccinia-infected cells. J Immunol 2002;169:6733-42.
27. Winau F, Weber S, Sad S et al. Apoptotic vesicles cross-prime CD8 T cells and protect against tuberculosis. Immunity 2006;24:105-17.
28. Schulz O, Diebold SS, Chen M et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005;433:887-92.
29. Datta SK, Redecke V, Prilliman KR et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 2003;170:4102-10.
30. Datta SK, Raz E. Induction of antigen cross-presentation by Toll-like receptors. Springer Semin Immunopathol 2005;26:247-55.
31. Chen M, Barnfield C, Naslund TI, Fleeton MN, Liljestrom P. MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells. J Virol 2005;79:2964-72.
32. Heath WR, Belz GT, Behrens GM et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004;199:9-26.
33. Yewdell JW, Hill AB. Viral interference with antigen presentation. Nat Immunol 2002;3:1019-25.
34. Basta S, Chen W, Bennink JR, Yewdell JW. Inhibitory effects of cytomegalovirus proteins US2 and US11 point to contributions from direct priming and cross-priming in induction of vaccinia virus-specific CD8(+) T cells. J Immunol 2002;168:5403-8.
35. Basta S, Bennink JR. A survival game of hide and seek: cytomegaloviruses and MHC class I antigen presentation pathways. Viral Immunol 2003;16:231-42.
36. Gold MC, Munks MW, Wagner M et al. Murine cytomegalovirus interference with antigen presentation has little effect on the size or the effector memory phenotype of the CD8 T cell response. J Immunol 2004;172:6944-53.
37. + CTL following exposure to vaccinia virus via different routes. J Immunol 2002;169:4222-9.
38. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
39. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A 1993;90:4942-6.
40. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997;158:2723-30.
41. Heit A, Huster KM, Schmitz F, Schiemann M, Busch DH, Wagner H. CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol 2004;172:1501-7.
42. Ke Y, Kapp JA. Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptor-mediated uptake. J Exp Med 1996;184:1179-84.
43. + T cells results in antigen-specific T-cell tolerance. Nat Med 2000;6:1348-54.
44. + T cell responses to bacterial antigens. J Immunol 2004;173:1994-2002.
45. Potter NS, Harding CV. Neutrophils process exogenous bacteria via an alternate class I MHC processing pathway for presentation of peptides to T lymphocytes. J Immunol 2001;167:2538-46.
46. Hon H, Oran A, Brocker T, Jacob J. B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. J Immunol 2005;174:5233-42.
47. Cho JH, Youn JW, Sung YC. Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. J Immunol 2001;167:5549-57.
48. Schuurhuis DH, van Montfoort N, Ioan-Facsinay A et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol 2006;176:4573-80.
49. den Haan JM, Bevan MJ. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med 2002;196:817-27.
50. Schuurhuis DH, IoanFacsinay A, Nagelkerken B et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8(+) CTL responses in vivo. J Immunol 2002;168:2240-6.
51. Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol 2004;16:21-5.
52. Medzhitov R, Janeway CA Jr. Innate immune recognition and control of adaptive immune responses. Semin Immunol 1998;10:351-3.
53. Katz SC, Pillarisetty VG, Bleier JI, Shah AB, DeMatteo RP. Liver sinusoidal endothelial cells are insufficient to activate T cells. J Immunol 2004;173:230-5.
54. Tokita D, Shishida M, Ohdan H et al. Liver sinusoidal endothelial cells that endocytose allogeneic cells suppress T cells with indirect allospecificity. J Immunol 2006;177:3615-24.
55. Marelli-Berg FM, Jarmin SJ. Antigen presentation by the endothelium: a green light for antigen-specific T cell trafficking? Immunol Lett 2004;93:109-13.
56. Limmer A, Ohl J, Wingender G et al. Cross-presentation of oral antigens by liver sinusoidal endothelial cells leads to CD8 T cell tolerance. Eur J Immunol 2005;35:2970-81.
57. Bagai R, Valujskikh A, Canaday DH et al. Mouse endothelial cells cross-present lymphocyte-derived antigen on class I MHC via a TAP1- and proteasome-dependent pathway. J Immunol 2005;174:7711-5.
58. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002;2:965-75.
59. Pozzi LA, Maciaszek JW, Rock KL. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol 2005;175:2071-81.
60. Basta S, Knoetig SM, Spagnuolo-Weaver M, Allan G, McCullough KC. Modulation of monocytic cell activity and virus susceptibility during differentiation into macrophages. J Immunol 1999;162:3961-9.
61. Tacke F, Ginhoux F, Jakubzick C, van Rooijen N, Merad M, Randolph GJ. Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. J Exp Med 2006;203:583-97.
62. Houde M, Bertholet S, Gagnon E et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003;425:402-6.
63. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-64.
64. Villadangos JA, Heath WR. Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm. Semin Immunol 2005;17:262-72.
65. Jung S, Unutmaz D, Wong P et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 2002;17:211-20.
66. Probst HC, van den Broek M. Priming of CTLs by lymphocytic choriomeningitis virus depends on dendritic cells. J Immunol 2005;174:3920-4.
67. Belz GT, Behrens GMN, Smith CM et al. The CD8 alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002;196:1099-104.
68. Pooley JL, Heath WR, Shortman K. Cutting edge: Intravenous soluble antigen is presented to CD4 T cells by CD8()) dendritic cells, but cross-presented to CD8 T cells by CD8(+) dendritic cells. J Immunol 2001;166:5327-30.
69. Smith CM, Belz GT, Wilson NS et al. Cutting edge: conventional CD8 alpha(+) dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J Immunol 2003;170:4437-40.
70. Belz GT, Smith CM, Eichner D et al. Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol 2004;172:1996-2000.
71. Moron G, Rueda P, Casal I, Leclerc C. CD8 alpha()) CD11b(+) dendritic cells present exogenous virus-like particles to CD8(+) T cells and subsequently express CD8 alpha and CD205 molecules. J Exp Med 2002;195:1233-45.
72. den Haan JMM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000;192:1685-95.
73. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006.
74. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-9.
75. Blachere NE, Darnell RB, Albert ML. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol 2005;3:e185.
76. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-34.
77. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002;195:125-33.
78. + T cells. J Immunother 2006;29:41-52.
79. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 2001;166:3717-23.
80. Schulz O, Reis e Sousa C. Cross-presentation of cell-associated antigens by CD8alpha+ dendritic cells is attributable to their ability to internalize dead cells. Immunology 2002;107:183-9.
81. + dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 2002;195:1289-302.
82. Pulendran B. Immune activation: death, danger and dendritic cells. Curr Biol 2004;14:R30-2.
83. Albert ML. Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol 2004;4:223-31.
84. Bosnjak L, Miranda-Saksena M, Koelle DM, Boadle RA, Jones CA, Cunningham AL. Herpes simplex virus infection of human dendritic cells induces apoptosis and allows cross-presentation via uninfected dendritic cells. J Immunol 2005;174:2220-7.
85. Matzinger P. Essay 1: the danger model in its historical context. Scand J Immunol 2001;54:4-9.
86. Li M, Davey GM, Sutherland RM et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001;166:6099-103.
87. Shen L, Rock KL. Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci U S A 2004;101:3035-40.
88. Burgdorf S, Lukacs-Kornek V, Kurts C. The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol 2006;176:6770-6.
89. Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TN. Antigen bias in T cell cross-priming. Science 2004;304:1314-7.
90. Khan S, de Giuli R, Schmidtke G et al. Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J Immunol 2001;167:4801-4.
91. Donohue KB, Grant JM, Tewalt EF et al. Cross-priming utilizes antigen not available to the direct presentation pathway. Immunology 2006;119:63-73.
92. Janda J, Schoneberger P, Skoberne M, Messerle M, Russmann H, Geginat G. Cross-presentation of Listeria-derived CD8 T cell epitopes requires unstable bacterial translation products. J Immunol 2004;173:5644-51.
93. Zheng H, Li Z. Cutting Edge: cross-presentation of cell-associated antigens to MHC class I molecule is regulated by a major transcription factor for heat shock proteins. J Immunol 2004;173:5929-33.
94. Shi H, Cao T, Connolly JE et al. Hyperthermia enhances CTL cross-priming. J Immunol 2006;176:2134-41.
95. Groothuis TA, Neefjes J. The many roads to cross-presentation. J Exp Med 2005;202:1313-8.
96. + T cells. Nat Immunol 2005;6:593-9.
97. Nicchitta CV. Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity. Nat Rev Immunol 2003;3:427-32.
98. + T cell response to a subdominant tumor antigen epitope. J Immunol 2005;175:700-12.
99. Storni T, Bachmann MF. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison. J Immunol 2004;172:6129-35.
100. Krysko DV, Denecker G, Festjens N et al. Macrophages use different internalization mechanisms to clear apoptotic and necrotic cells. Cell Death Differ 2006;13:2011-22.